These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

502 related items for PubMed ID: 31809827

  • 1. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
    Reich K, Griffiths CEM, Gordon KB, Papp KA, Song M, Randazzo B, Li S, Shen YK, Han C, Kimball AB, Armstrong AW, Foley P, Blauvelt A.
    J Am Acad Dermatol; 2020 Apr; 82(4):936-945. PubMed ID: 31809827
    [Abstract] [Full Text] [Related]

  • 2. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
    Reich K, Papp KA, Armstrong AW, Wasfi Y, Li S, Shen YK, Randazzo B, Song M, Kimball AB.
    Br J Dermatol; 2019 May; 180(5):1039-1049. PubMed ID: 30485400
    [Abstract] [Full Text] [Related]

  • 3. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
    Reich K, Armstrong AW, Foley P, Song M, Miller M, Shen YK, You Y, Han C, Gordon KB.
    Am J Clin Dermatol; 2020 Dec; 21(6):881-890. PubMed ID: 32910434
    [Abstract] [Full Text] [Related]

  • 4. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
    Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA.
    Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277
    [Abstract] [Full Text] [Related]

  • 5. Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2.
    Kim BS, Jo SJ, Youn S, Reich K, Saadoun C, Chang CL, Yang YW, Huang YH, Tsai TF.
    Dermatol Ther (Heidelb); 2023 Nov; 13(11):2721-2737. PubMed ID: 37750995
    [Abstract] [Full Text] [Related]

  • 6. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.
    Blauvelt A, Tsai TF, Langley RG, Miller M, Shen YK, You Y, Yang YW, Papp KA, Puig L.
    J Am Acad Dermatol; 2022 Apr; 86(4):827-834. PubMed ID: 34798201
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

  • 8. Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
    Griffiths CEM, Papp KA, Kimball AB, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.
    J Drugs Dermatol; 2018 Aug 01; 17(8):826-832. PubMed ID: 30124721
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis: post-hoc analysis from the phase III, double-blind, placebo- and active-comparator-controlled VOYAGE 1/2 trials.
    Youn SW, Yu DY, Kim TY, Kim BS, Lee SC, Lee JH, Choe YB, Lee JH, Choi JH, Roh JY, Jo SJ, Lee ES, Shin MK, Lee MG, Jiang J, Lee Y.
    J Dermatolog Treat; 2022 Feb 01; 33(1):535-541. PubMed ID: 32419536
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB.
    J Am Acad Dermatol; 2017 Mar 01; 76(3):405-417. PubMed ID: 28057360
    [Abstract] [Full Text] [Related]

  • 11. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
    Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, You Y, Han C, Yang YW, Foley P, Griffiths CEM.
    Br J Dermatol; 2021 Dec 01; 185(6):1146-1159. PubMed ID: 34105767
    [Abstract] [Full Text] [Related]

  • 12. Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.
    Puig L, Wu JJ, Gooderham MJ, You Y, Shen YK, Randazzo B, Kerdel F.
    J Dermatolog Treat; 2021 Aug 01; 32(5):484-491. PubMed ID: 31613178
    [Abstract] [Full Text] [Related]

  • 13. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A.
    Lancet; 2019 Sep 07; 394(10201):831-839. PubMed ID: 31402114
    [Abstract] [Full Text] [Related]

  • 14. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
    Ohtsuki M, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H.
    J Dermatol; 2018 Sep 07; 45(9):1053-1062. PubMed ID: 29905383
    [Abstract] [Full Text] [Related]

  • 15. Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure.
    Lebwohl MG, Merola JF, Rowland K, Miller M, Yang YW, Yu J, You Y, Chan D, Thaçi D, Langley RG.
    Br J Dermatol; 2023 Jul 07; 189(1):42-52. PubMed ID: 37022762
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.
    Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, Shen YK, You Y, Griffiths CEM.
    Br J Dermatol; 2018 Jan 07; 178(1):132-139. PubMed ID: 28940259
    [Abstract] [Full Text] [Related]

  • 17. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1.
    Griffiths CEM, Papp KA, Song M, Miller M, You Y, Shen YK, Han C, Blauvelt A.
    J Dermatolog Treat; 2022 Mar 07; 33(2):848-856. PubMed ID: 32660282
    [Abstract] [Full Text] [Related]

  • 18. Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2.
    Foley P, Reich K, Blauvelt A, Bagel J, Langley RG, Miller M, Ramachandran P, Yang YW, Shen YK, You Y, Lebwohl M, Griffiths CEM.
    J Drugs Dermatol; 2021 Aug 01; 20(8):855-860. PubMed ID: 34397205
    [Abstract] [Full Text] [Related]

  • 19. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
    Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, You Y, Shen YK, Reich K.
    J Eur Acad Dermatol Venereol; 2018 Nov 01; 32(11):1940-1949. PubMed ID: 29706008
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
    Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.
    JAMA Dermatol; 2018 Jun 01; 154(6):676-683. PubMed ID: 29799960
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.